BioSpace News Archive

Valo Health LLC (Valo), the technology company that is using human-centric data and machine learning computation to transform and accelerate the drug discovery and development process, today announced that David Berry, Ph.D., founder and Chief Executive Officer of Valo will participate in the Credit Suisse Healthcare Innovators Series: The Intersection of Drug Discovery,

Stimdia Medical, Inc., an emerging leader in the development of technology to reduce weaning time for patients on mechanical ventilation, today announced the company’s pdSTIM™ System has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA)

Verantos announced today a collaboration with Amgen to launch an advanced real-world evidence (RWE) program focused on high-validity observational studies.

Segra International Corp, a leading cannabis agriculture technology company, is pleased to announce the development and validation of an in-house assay for Hop Latent Viroid (HLVd) through leveraging the highly qualified capabilities of their in-house molecular biology laboratory, under the leadership of Segra’s Chief Science Officer Dr. John Brunstein

Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results, including an update on its CD47 clinical programs, for the year ended December 31, 2020.

vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mechanistic study exploring the effects of TTP399 on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the fourth quarter and full year 2020 and provided a corporate and clinical update.

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate (ORR)

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it will release its fourth quarter and full-year 2020 financial results after market close on Thursday, March 25, 2021. An accompanying conference call will be hosted by Dr. Horst G. Zerbe, Chief Executive Officer

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared new results from the ongoing study of SRP-9003 (rAAVrh74.MHCK7.hSGCB), the Company’s investigational gene therapy for limb-girdle muscular dystrophy Type 2E (LGMD2E).